#None #Telix Pharmaceuticals #Hagens Berman #TLX

Urgent Notice for Telix Investors: Class Action Suit Insights

In a recent development that has alarmed many investors, Hagens Berman, a national law firm dedicated to shareholder rights, is reaching out to investors of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). The firm has highlighted the approaching deadline of January 9, 2026, for potential lead plaintiffs in a pending securities class action lawsuit. This legal action stems from significant regulatory setbacks that have impacted Telix's market performance, leading to a dramatic 21% plunge in its stock value.

Regulatory Setbacks Affecting Telix Pharmaceuticals

The core of the issue revolves around a series of troubling events, including an SEC subpoena concerning the company’s disclosures related to its prostate cancer therapeutic candidates (specifically TLX591 and TLX592). This subpoena raises serious questions regarding the accuracy and transparency of the information being provided to shareholders and the public. These developments suggest that Telix may have overstated its progress regarding critical drug developments.

To add to the complications, the FDA issued a Complete Response Letter (CRL) that rejected the Zircaix application due to major deficiencies in the areas of Chemistry, Manufacturing, and Controls (CMC). The issuance of Form 483 notices to both of Telix’s third-party manufacturing partners highlights compliance issues that were alleged to have been concealed from the investors. These shortcomings have led to a significant loss of trust, prompting investors to reconsider their investments in Telix, especially in light of the company’s assertions of having a broad global manufacturing capability.

The Impacts on Investors

Hagens Berman's complaint alleges that the misleading statements from Telix, regarding both the advancement of its therapeutic candidates and the reliability of its supply chain partners, have materially misled investors. The dramatic corrective disclosures have not only harmed investor sentiment but also inflicted substantial financial losses on those who purchased Telix ADSs during the official Class Period, which spans from February 21, 2025, to August 28, 2025. The cumulative effect of these revelations is reflected in the sharp decline in the value of Telix ADSs, marked by the notable 21% drop following the latest regulatory news.

Next Steps for Affected Investors

For investors who have suffered losses due to Telix's alleged misstatements and failures, Hagens Berman strongly encourages you to reach out for a consultation. Led by attorney Reed Kathrein, the firm is ready to provide advice and support to those affected by these disclosures. The firm’s extensive experience in handling complex litigation and ensuring corporate accountability makes them a credible advocate for aggrieved investors.

With a track record of securing over $2.9 billion for clients in similar matters, Hagens Berman stands out in the field of plaintiff litigation. If you believe you qualify as a lead plaintiff or have incurred losses while investing in Telix during the defined period, the time to act is now.

For more details about submitting your Telix investment losses or to discuss potential claims, you can contact Reed Kathrein directly at 844-916-0895 or via email. Additionally, whistleblowers with non-public information that may aid the investigation are encouraged to come forward, with potential financial rewards available through the SEC’s Whistleblower program.

In the fast-paced realm of pharmaceutical investments, staying informed and proactive can substantially affect outcomes. As the January 9 deadline looms, affected Telix investors must assess their options swiftly to protect their interests.